Evidence map›Paper›PMID 34943776›Full record

ArticleCells2021

Deep Learning Analyses to Delineate the Molecular Remodeling Process after Myocardial Infarction.

Oriol Iborra-Egea, Carolina Gálvez-Montón, Cristina Prat-Vidal, Santiago Roura, Carolina Soler-Botija, Elena Revuelta-López, Gemma Ferrer-Curriu, Cristina Segú-Vergés, Araceli Mellado-Bergillos, Pol Gomez-Puchades and 2 more

Open access · goldAbstract read
In one paragraph

Article in Cells, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
0.3field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 6 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Oriol Iborra-EgeaICREC Research Program, Health Sciences Research Institute Germans Trias i Pujol, Universitat Autònoma de Barcelona, 08916 Barcelona, Spain.
Carolina Gálvez-MontónICREC Research Program, Health Sciences Research Institute Germans Trias i Pujol, Universitat Autònoma de Barcelona, 08916 Barcelona, Spain.ORCID 0000-0003-2254-9371
Cristina Prat-VidalICREC Research Program, Health Sciences Research Institute Germans Trias i Pujol, Universitat Autònoma de Barcelona, 08916 Barcelona, Spain.ORCID 0000-0002-5621-1101
Santiago RouraICREC Research Program, Health Sciences Research Institute Germans Trias i Pujol, Universitat Autònoma de Barcelona, 08916 Barcelona, Spain.
Carolina Soler-BotijaICREC Research Program, Health Sciences Research Institute Germans Trias i Pujol, Universitat Autònoma de Barcelona, 08916 Barcelona, Spain.
Elena Revuelta-LópezICREC Research Program, Health Sciences Research Institute Germans Trias i Pujol, Universitat Autònoma de Barcelona, 08916 Barcelona, Spain.
Gemma Ferrer-CurriuICREC Research Program, Health Sciences Research Institute Germans Trias i Pujol, Universitat Autònoma de Barcelona, 08916 Barcelona, Spain.
Cristina Segú-VergésAnaxomics Biotech S.L., Diputació 237 1r 1a, 08007 Barcelona, Spain.ORCID 0000-0002-8215-872X
Araceli Mellado-BergillosICREC Research Program, Health Sciences Research Institute Germans Trias i Pujol, Universitat Autònoma de Barcelona, 08916 Barcelona, Spain.
Pol Gomez-PuchadesICREC Research Program, Health Sciences Research Institute Germans Trias i Pujol, Universitat Autònoma de Barcelona, 08916 Barcelona, Spain.
Paloma GastelurrutiaICREC Research Program, Health Sciences Research Institute Germans Trias i Pujol, Universitat Autònoma de Barcelona, 08916 Barcelona, Spain.
Antoni Bayes-GenisICREC Research Program, Health Sciences Research Institute Germans Trias i Pujol, Universitat Autònoma de Barcelona, 08916 Barcelona, Spain.
Universitat Autònoma de Barcelona · ESAnaxomics (Spain) · ESUniversitat de Vic - Universitat Central de Catalunya · ES

Funding

Agència de Gestió d'Ajuts Universitaris i de Recerca 2017-SGR-483, 2019PROD00122Centro de Investigación en Red en Enfermedades Cardiovasculares CB16/11/00403Fundación Bancaria Caixa d'Estalvis i Pensions de Barcelona HR17-00627, CI20-00230Instituto de Salud Carlos III PI17/01487, PIC18/00014, ICI19/00039, PI18/00256, PI18/01227, ICI20/00135Red de Terapia Celular-TerCel RD16/0011/0006Spanish Ministry of Economy and Competitiveness-MICINN SAF2017-84324-C2-1-R; PID2019-110137RB-I00
6 · The paper itself

Abstract

Specific proteins and processes have been identified in post-myocardial infarction (MI) pathological remodeling, but a comprehensive understanding of the complete molecular evolution is lacking. We generated microarray data from swine heart biopsies at baseline and 6, 30, and 45 days after infarction to feed machine-learning algorithms. We cross-validated the results using available clinical and experimental information. MI progression was accompanied by the regulation of adipogenesis, fatty acid metabolism, and epithelial-mesenchymal transition. The infarct core region was enriched in processes related to muscle contraction and membrane depolarization. Angiogenesis was among the first morphogenic responses detected as being sustained over time, but other processes suggesting post-ischemic recapitulation of embryogenic processes were also observed. Finally, protein-triggering analysis established the key genes mediating each process at each time point, as well as the complete adverse remodeling response. We modeled the behaviors of these genes, generating a description of the integrative mechanism of action for MI progression. This mechanistic analysis overlapped at different time points; the common pathways between the source proteins and cardiac remodeling involved IGF1R, RAF1, KPCA, JUN, and PTN11 as modulators. Thus, our data delineate a structured and comprehensive picture of the molecular remodeling process, identify new potential biomarkers or therapeutic targets, and establish therapeutic windows during disease progression.

Indexed as

AdipogenesisAlgorithmsAnimalsBiopsyDeep LearningDisease Models, AnimalEpithelial-Mesenchymal TransitionFatty AcidsHumansMicroarray AnalysisModels, MolecularMuscle ContractionMyocardial InfarctionMyocardiumProto-Oncogene Proteins c-junProto-Oncogene Proteins c-rafFatty AcidsIGF1R protein, humanJUN protein, humanProto-Oncogene Proteins c-junProto-Oncogene Proteins c-rafRaf1 protein, humanReceptor, IGF Type 1deep learninggene regulationmyocardial infarctiontranscriptomics

Identifiers

PMID34943776
PMCPMC8699769
OpenAlexW3215736090

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.